TTrialPathMatch Me to Trials
← Back to trials
RecruitingFriedreich AtaxiaCardiomyopathy

Clinical Course Of Disease In Participants With FA-CM

Eligible age

6+ yrs

Accepts

All genders

Locations

8 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)

Sponsor: Lexeo Therapeutics

You may qualify if…

  • ✓ Male or female, ages ≥6 years at the time of signing the informed consent (and assent, if applicable).
  • ✓ Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles or compound heterozygous), with onset of FA occurring at ≤25 years of age
  • ✓ Confirmed left ventricular hypertrophy (LVH)
  • ✓ Left ventricular ejection fraction ≥30%

You may not qualify if…

  • ✕ Presence of other form(s) of CM contributing to heart failure (HF), clinically significant cardiac anatomic abnormality or congenital cardiac malformation, clinically significant coronary artery, uncorrected, hemodynamically significant primary structural valvular disease not due to CM
  • ✕ Currently receiving intermittent or continuous intravenous (IV) inotrope infusion, presence of a ventricular assist device, or history of prior heart transplantation
  • ✕ Contraindication to cMRI, participants \<12 years of age who cannot complete the cMRI without sedation will instead undergo ECHOs and are exempt from this criterion.
  • ✕ Prior organ transplantation
  • ✕ Initiation of cardiac resynchronization therapy (CRT) within 6 months prior to screening.
  • ✕ History of prior gene transfer or cell therapy.
  • ✕ Poorly controlled diabetes (hemoglobin A1c ≥8%)
  • ✕ Active hematologic or solid organ malignancy

Where it's recruiting

California

La Jolla

Florida

Tampa

Indiana

Indianapolis

Minnesota

Rochester

Missouri

St Louis

Ohio

Cincinnati

Oregon

Portland

Source: ClinicalTrials.gov · NCT06865482 · last updated 2026-10-19